Regulation and function of angiogenic factors in chronic lymphocytic leukemia

Increased Serum Von Willebrand Levels in Chronic Lymphocytic Leukemia (CLL) Patients Are Related To a Shorter Time to Treatment

“…With regard to the effects of vWF serum levels, we did not found any other report than ours in published medical literature. However, an adverse prognostic impact of high serum vWF levels was reported in other B-cell lymphoproliferative disorders such as AL amyloidosis [5] and Waldenstrom's macroglobulinemia.…”

“…Based on the potential contribution of neoangiogenesis in CLL pathogenesis, anti-angiogenic agents for CLL patients' treatment seemed promising [5]. Many agents were used but the most interesting were anti-VEGF (Bevacizumab) and IMiDs (lenalidomide); however, as monotherapy, treatment was not as efficient as expected and accompanied with side effects such as cardiovascular complications for the first and flair for the second.…”